Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nilofer Azad

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Molecular & Cellular Proteomics : MCP|March 2, 2013
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohortNilofer Azad, Minshu Yu, Ben Davidson, et al.
Elife|May 20, 2025
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1Jordina Rincon-Torroella, Marco Dal Molin, Brian Mog, et al.
Investigational New Drugs|May 23, 2012
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancerNilofer Azad, Arvind Dasari, John Arcaroli, et al.
Journal of the National Cancer Institute|May 21, 2014
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analysesJung-Min Lee, John L Hays, Christina M Annunziata, et al.
Journal of the American College of Radiology : JACR|March 6, 2016
ACR Appropriateness Criteria Radiologic Management of Hepatic MalignancyBrian E Kouri, Ross A Abrams, Waddah B Al-Refaie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 17, 2022
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical OpinionDebyani Chakravarty, Amber Johnson, Jeffrey Sklar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2018
A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to IrinotecanValerie Lee, Judy Wang, Marianna Zahurak, et al.
International Journal of Surgical Oncology|August 31, 2012
Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visitsSalma K Jabbour, Shyamal Patel, Joseph M Herman, et al.
American Journal of Clinical Oncology|February 24, 2017
ACR Appropriateness Criteria® Resectable Pancreatic CancerWilliam E Jones, W Waren Suh, May Abdel-Wahab, et al.
International Journal of Radiation Oncology, Biology, Physics|August 25, 2019
Executive Summary of the American Radium Society Appropriate Use Criteria for Local Excision in Rectal CancerSuzanne Russo, Christopher J Anker, May Abdel-Wahab, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Molecular & Cellular Proteomics : MCP|March 2, 2013
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohortNilofer Azad, Minshu Yu, Ben Davidson, et al.
Elife|May 20, 2025
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1Jordina Rincon-Torroella, Marco Dal Molin, Brian Mog, et al.
Investigational New Drugs|May 23, 2012
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancerNilofer Azad, Arvind Dasari, John Arcaroli, et al.
Journal of the National Cancer Institute|May 21, 2014
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analysesJung-Min Lee, John L Hays, Christina M Annunziata, et al.
Journal of the American College of Radiology : JACR|March 6, 2016
ACR Appropriateness Criteria Radiologic Management of Hepatic MalignancyBrian E Kouri, Ross A Abrams, Waddah B Al-Refaie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 17, 2022
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical OpinionDebyani Chakravarty, Amber Johnson, Jeffrey Sklar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2018
A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to IrinotecanValerie Lee, Judy Wang, Marianna Zahurak, et al.
International Journal of Surgical Oncology|August 31, 2012
Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visitsSalma K Jabbour, Shyamal Patel, Joseph M Herman, et al.
American Journal of Clinical Oncology|February 24, 2017
ACR Appropriateness Criteria® Resectable Pancreatic CancerWilliam E Jones, W Waren Suh, May Abdel-Wahab, et al.
International Journal of Radiation Oncology, Biology, Physics|August 25, 2019
Executive Summary of the American Radium Society Appropriate Use Criteria for Local Excision in Rectal CancerSuzanne Russo, Christopher J Anker, May Abdel-Wahab, et al.
Pageof 5